~~<i id='1952B8FD7E'><strike id='1952B8FD7E'><tt id='1952B8FD7E'><pre id='1952B8FD7E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

Wikipedia

author：explore 2025-09-30 23:19:44 - browse：9

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why Medicare shouldn’t cover every FDA

entertainment

leisure time

hotspot

Sen.BernieSandersisaskinghiscolleaguestoissueasubpoenaoftwopharmaceuticalcompanyCEOs.KevinDietsch/Ge

WSS

Syphilis numbers in the United States reach record heights

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Vertex non

Readout Newsletter: The latest on Novavax, Merck, Bluebird

First recipient of genetically engineered pig kidney has died

New clues to why women have higher risk of autoimmune disorders

knowledge

Wikipedia

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Steward Health Care files for bankruptcy

Medical leaders decry Supreme Court decision on affirmative action

Why Medicare shouldn’t cover every FDA

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dairy farmers resist CDC push for PPE against bird flu virus

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare says breakthrough device reimbursement rule to come by summer

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study: People of West African ancestry at greater risk of cardiac amyloidosis

leisure time

Researchers on aging grapple with how to calculate biological age

CDC wastewater surveillance dashboard to track bird flu hotspots

Philips to halt sales of sleep apnea machines in U.S.

Boston competes with Raleigh

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Software glitch causes Tandem insulin pump to shutdown, FDA warns

leisure time

hotspot

hotspot

hotspot